CA
NZ
UK
AU
IND
US
Immuneering Corp reported a net loss of $17.3 million for the second quarter of 2026, slightly better than the expected $0.27 per share loss. Investors gain reassurance from the solid cash position of $182.7 million, providing operational runway until 2029 amid ongoing pivotal trials.Key …
Elite Health Systems Inc. has approved a significant $525,000 subordinated note agreement with its CEO, Dr. Prasad Jeereddi. This agreement, finalized on July 31, 2026, allows the company to expand its financial resources, enabling potential investments to reach an aggregate total of $1.5 million …
Entrada Therapeutics (NASDAQ: TRDA) posted earnings per share of $‑0.95 for the quarter ended June 30, outpacing the $‑1.06 consensus. With a market capitalization of about $274 million, the EPS surprise narrows the loss per share and gives investors a more favorable view of …
The financial results serve as a critical indicator of operational efficiency and potential investor confidence. Increased collaboration revenues, now at $11.9 million from $3.6 million, showcase a positive trend in revenue generation, enhancing the company’s attractiveness in the biotech sector.
Elanco Animal Health Inc (NYSE: ELAN) posted adjusted earnings per share of $0.34 for the quarter ended June 30, beating the $0.27 consensus. The result sits on a backdrop of $1,368 million in revenue, a 10% year‑over‑year increase and an 8% rise on an …
Eli Lilly has raised its price target following a standout second quarter, underscoring the strength of its GLP-1 drug portfolio. This upward adjustment reflects strong revenue growth, projecting continued positive momentum for the company in the coming quarters. Investors are taking notice, with expectations …
- Black Diamond Therapeutics announced an extension of its cash runway, providing additional operational flexibility. - The company reported strong central nervous system (CNS) activity for its lead candidate, signaling potential therapeutic advantage. - Investor interest has risen sharply following the cash‑runway extension and …
Caris Life Sciences (NASDAQ: CAI) announced Q2 2026 revenue of $263.7 million, a 45% increase from the comparable period last year, while earnings per share came in at $0.00 versus a $0.01 consensus. The surge lifts the company’s full‑year revenue guidance to a range …
Carlsmed, Inc. (NASDAQ: CARL) announced a strong second quarter 2026, reporting revenue of $18.9 million, which marks a remarkable 57% increase from $12.1 million in the same period last year. This strong performance signals heightened investor confidence and suggests that Carlsmed is gaining substantial …
Clover Health Investments, Corp. has announced a net income of $28 million for the second quarter, a remarkable turnaround of $39 million compared to the same period last year. This financial performance resulted in total revenues of $743 million, representing a strong 56% increase …
Please wait processing your request...